<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433497</url>
  </required_header>
  <id_info>
    <org_study_id>AB07002</org_study_id>
    <nct_id>NCT01433497</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis</brief_title>
  <official_title>A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day
      versus placebo in the treatment of patients with primary progressive multiple sclerosis or
      relapse-free secondary progressive multiple sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective
      effect through its activity on mast cells and other non-neuronal cells of the central nervous
      system, with subsequent modulation of inflammatory and neurodegenerative processes. The
      objective of this study is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day
      versus matched placebo, or masitinib at 4.5 mg/kg/day with a dose escalation to 6 mg/kg/day
      after 3 months of treatment versus matched placebo, in the treatment of patients with primary
      progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.
      Approximately 600 patients will be randomized into four treatment groups with a 2:2:1:1
      design. The primary outcome measure is the Expanded Disability Status Scale (EDSS) after 96
      weeks of treatment in the overall study population with subgroup analysis performed in
      stratum (primary progressive multiple sclerosis / secondary progressive multiple sclerosis).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EDSS</measure>
    <time_frame>96 weeks</time_frame>
    <description>Expanded Disability Status Scale (EDSS) after 96 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MSQOL-54</measure>
    <time_frame>96 weeks</time_frame>
    <description>Multiple Sclerosis Quality of Life 54 items (MSQOL-54)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSFC</measure>
    <time_frame>96 weeks</time_frame>
    <description>Multiple Sclerosis Functional Composite (MSFC)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">656</enrollment>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <condition>Multiple Sclerosis, Primary Progressive</condition>
  <condition>Multiple Sclerosis, Relapse Free</condition>
  <arm_group>
    <arm_group_label>Experimental Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo given orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <arm_group_label>Experimental Arm A</arm_group_label>
    <arm_group_label>Experimental Arm B</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Comparator A</arm_group_label>
    <arm_group_label>Placebo Comparator B</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

        - Patient suffering from either primary progressive or secondary progressive multiple
        sclerosis without relapse within 2 years before inclusion according to the revised
        McDonald's criteria.

        Main exclusion criteria:

        - Patient suffering from a disease other than MS that would better explain the patient's
        neurological clinical signs and symptoms and/or MRI lesions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Vermersch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Salengro, Lille, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;St. Ivan Rilski&quot; University Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHICL hopital ST vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>D-35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehibilitation Center &quot;KENTAVROS&quot;</name>
      <address>
        <city>Volos</city>
        <zip>382 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Lublin II</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Clubul Sănătăţii</name>
      <address>
        <city>Campulung</city>
        <zip>115100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 12, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <disposition_first_submitted>March 30, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 30, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 3, 2020</disposition_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>primary progressive</keyword>
  <keyword>relapse-free</keyword>
  <keyword>secondary progressive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

